BioSpace News Archive

Sanofi has in principle reached a settlement related to its discontinued heartburn drug Zantac, though the French pharma did not disclose the financial terms of the deal.

Three Biopharma firms disclosed concerns about how emerging geopolitical tensions between the U.S. and China might impact their business with the contract manufacturer.

The American Association for Cancer Research has invited drug developers and investors to intermingle with the academics who typically attend its annual conference.

A Delaware judge on Wednesday agreed with Roivant subsidiary Arbutus and Genevant’s interpretation of specific patent claims regarding the lipid nanoparticle delivery system used by Moderna’s COVID-19 vaccine.

Amid a flurry of deals in the antibody-drug conjugate space, Merck KGaA is getting in on the action with a partnership with Caris Life Sciences to accelerate the discovery and development of first-in-class ADCs for oncology.

Basilea Pharmaceutica received FDA approval for its antibiotic Zevtera in three indications Wednesday, finally getting the drug across the finish line a decade and a half after the agency rejected an earlier submission.

Analysts and attendees aren’t expecting groundbreaking data at the American Association for Cancer Research’s annual conference this year, but for many, that isn’t the point.

Following disappointing late-stage data, Amylyx on Thursday said it is withdrawing the company’s amyotrophic lateral sclerosis drug Relyvrio from the U.S. and Canadian markets and cutting its workforce by approximately 70%.

Basilea Pharmaceutica Ltd, Allschwil announced that the US Food and Drug Administration approved ZEVTERA®, for the treatment of adult patients with Staphylococcus aureus bloodstream infections, including those with right-sided infective endocarditis, and adult patients with acute bacterial skin and skin structure infections and for adult and pediatric patients with community-acquired bacterial pneumonia.

Vicore Pharma Holding The shareholders of Vicore Pharma Holding AB, Reg. No. 556680-3804, with its registered offices in Stockholm, are summoned to the annual general meeting on Tuesday 7 May 2024 at 14.00 in the premises of the law firm Vinge at Smålandsgatan 20, SE-111 46 Stockholm, Sweden.